Correlation Between Inozyme Pharma and Zenas BioPharma,

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Inozyme Pharma and Zenas BioPharma, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Inozyme Pharma and Zenas BioPharma, into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Inozyme Pharma and Zenas BioPharma, Common, you can compare the effects of market volatilities on Inozyme Pharma and Zenas BioPharma, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inozyme Pharma with a short position of Zenas BioPharma,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inozyme Pharma and Zenas BioPharma,.

Diversification Opportunities for Inozyme Pharma and Zenas BioPharma,

0.68
  Correlation Coefficient

Poor diversification

The 3 months correlation between Inozyme and Zenas is 0.68. Overlapping area represents the amount of risk that can be diversified away by holding Inozyme Pharma and Zenas BioPharma, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Zenas BioPharma, Common and Inozyme Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inozyme Pharma are associated (or correlated) with Zenas BioPharma,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Zenas BioPharma, Common has no effect on the direction of Inozyme Pharma i.e., Inozyme Pharma and Zenas BioPharma, go up and down completely randomly.

Pair Corralation between Inozyme Pharma and Zenas BioPharma,

Given the investment horizon of 90 days Inozyme Pharma is expected to generate 0.81 times more return on investment than Zenas BioPharma,. However, Inozyme Pharma is 1.23 times less risky than Zenas BioPharma,. It trades about 0.04 of its potential returns per unit of risk. Zenas BioPharma, Common is currently generating about -0.13 per unit of risk. If you would invest  177.00  in Inozyme Pharma on October 5, 2024 and sell it today you would earn a total of  108.00  from holding Inozyme Pharma or generate 61.02% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy15.59%
ValuesDaily Returns

Inozyme Pharma  vs.  Zenas BioPharma, Common

 Performance 
       Timeline  
Inozyme Pharma 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Inozyme Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in February 2025. The current disturbance may also be a sign of long term up-swing for the company investors.
Zenas BioPharma, Common 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Zenas BioPharma, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Etf's forward indicators remain very healthy which may send shares a bit higher in February 2025. The recent disarray may also be a sign of long period up-swing for the ETF investors.

Inozyme Pharma and Zenas BioPharma, Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Inozyme Pharma and Zenas BioPharma,

The main advantage of trading using opposite Inozyme Pharma and Zenas BioPharma, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inozyme Pharma position performs unexpectedly, Zenas BioPharma, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Zenas BioPharma, will offset losses from the drop in Zenas BioPharma,'s long position.
The idea behind Inozyme Pharma and Zenas BioPharma, Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.

Other Complementary Tools

Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume